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Introduction
Epidemiological studies have demonstrated that up to 10%
of individuals aged 65 years or older suffer from dementia,
most commonly from dementia of the Alzheimer type (DAT)
(1). Since our lifespans are increasing (2, 6), the relationship
between age and the prevalence of dementia suggests that
memory clinics and similar institutions will face a growing
challenge in the coming decades to identify the increasing
number of affected individuals. While the diagnosis of patients
in the late stages of the disease is straightforward, it is difficult
to distinguish early-stage dementia from healthy aging and
from depression. 
During the first decades of the last century, vascular
dementia (VaD) was cited as the most common cause of
dementia (7). However, many prospective clinicopathological
studies have since shown that AD is the most common cause of
dementia in the elderly (8). Based on recent clinicopathological
studies, dementia with Lewy bodies (DLB) has emerged as the
second most common degenerative pathology associated with
dementia, accounting for 10 - 25% of all cases (9-12). Vascular
pathology now appears to be the third most common cause of
dementia, accounting for roughly one-fifth of the number of
dementia cases (13, 14). However, the situation is not quite as
simple as this breakdown suggests, since vascular pathology
and AD often occur together to varying extents, a syndrome
called mixed dementia. Whether cognitive impairments due to
diastolic hypotension contribute to the development of VaD or
DAT remains to be established (6, 15). Furthermore, it has
become increasingly clear that various non-Alzheimer
degenerative conditions characterized by frontotemporal lobar
degeneration (FTLD) like  frontotemporal dementia account for
12 – 20% of all dementia cases (16-18). More recently,
argyrophilic grain disease (AgD) has been described as a late-
onset form of dementia accounting for roughly 5% of dementia
cases (19). However, many other, rarer forms of degenerative
dementias exist, among them senile dementia with tangles (20-
22). Although these entities have been subsumed in the FTLD
nomenclature, they have distinct clinical and pathological
features. 
The accurate clinical diagnosis of dementia is becoming
increasingly relevant as new treatment possibilities for
neurodegenerative disorders become available. However, the
clinical diagnosis remains an estimation of the underlying
neuropathology until the definitive diagnosis is established
upon autopsy. Studies investigating the diagnostic accuracy for
dementia have reported rates between 52 and 100 % for DAT
(2-4, 23-26) and between 21 and 95 % for VaD (2-4, 23, 25-
27). However, these studies included younger patients with few
comorbidities. The objectives of the present study were to
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determine the clinical diagnostic accuracy in a group of older
patients examined at the Memory Clinic University Hospital
Basel, Switzerland by comparing the clinical with the
neuropathological diagnoses, to determine the prevalence of the
different forms of dementia, and to investigate the relationship
between age at death and polymorbidity. The “gold standard”
for the determination of diagnoses was the neuropathological
findings.
Patients and methods
Memory Clinic
The aim of the Memory Clinic (MC) at the University
Hospital Basel, Switzerland, is to detect dementing disorders in
ambulatory elderly patients in an early stage of illness. The
clinical diagnostic process has been described elsewhere (28).
In the present study, we used the Mini Mental State
examination (MMS) to describe the severity of dementia [29]
and the Hachinski Ischemic Score (HIS) to assess
cerebrovascular morbidity (30).
Patients
Two hundred and twenty-one patients who had been
examined at the MC died during the observation period of the
current study (1986-1996). Between 1988 and 1997, 34 % (75
patients) were autopsied in the Department of Pathology,
University Hospital Basel, and 83 % of these patients (n = 62)
additionally underwent a neuropathological examination. The
study sample comprised 28 men and 34 women, their age at
death ranged between 58 and 97 years (mean age ± standard
deviation (SD) = 78.7 ± 8.2 years), and their mean MMS score
was 20 (SD = 6.3) an average of 3.2 years (SD = 2.3 years)
preceding death.
The clinical diagnosis of DAT relied on DSM-IV (the
Diagnostic and Statistical Manual of mental disorders IV) (31)
and NINCDS-ADRDA criteria (National Institute of
Neurological and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association) (32).
VaD was diagnosed using NINDS-AIREN criteria (National
Institute of Neurological Disorders and Stroke in collaboration
with L’Association Internationale pour la Recherche et
l’Enseignement en Neurosciences) (33), and published
consensus guidelines were employed to reach FTD (16) and
DLB (9) diagnoses. The diagnosis of Parkinson’s disease relied
on the cardinal symptoms of resting tremor, rigor and akinesia
or hypokinesia. AAMI was diagnosed according to the criteria
of Levy (45). Revised diagnoses, if made in the follow-up visit
scheduled one year after the first consultation, were employed
in the present study.
Neuropathology
Brains were immersed in 4 % phosphate buffered
formaldehyde (pH 7.4) for 2 weeks. After fixation, the brains
were sliced in the coronal plane and several tissue blocks were
taken from various parts of the brain and embedded in paraffin.
For the present study, we examined the following regions in
detail: the anterior hippocampus including the head and body of
the cornu ammonis, dentate gyrus, subiculum, entorhinal and
perirhinal cortices and parts of the gyrus fusiformis near the
rhinal sulcus. The posterior hippocampal region included the
body and tail of the cornu ammonis, the dentate gyrus the
subiculum and the parahippocampal gyrus with adjacent
temporobasal neocortex. Further regions investigated included
the frontal, fronto-orbital, rostral cingulate and occipital
cortices, the striatum, the amygdala, the medial forebrain nuclei
including the septal nuclei, various cerebral white matter
regions, the substantia nigra, the cerebellum and the brainstem
including the locus coeruleus and medulla oblongate.
Histological sections were stained with haematoxilin and eosin,
Holmes-Luxol, periodic acidic methamine silver stain for senile
plaques, and the Gallyas silvertechnique [34] for argyrophilic
neurofibrillary lesions. Histology was complemented by
various immunohistochemical stainings with antibodies against
phosphorylated tau (AT8), amyloid-beta protein, alpha-
synuclein and ubiquitin. The neuropathological diagnosis was
made based on published diagnostic criteria [35, 41]
Statistical method
Because of heterogeneity of diagnoses in the patient group
and the small cell sizes, we report mainly descriptive statistics.
The Chi-square test was employed to compare the distributions
of patients in different diagnostic groups and was calculated
with Statview, version 5, for Windows (www.statview.com/
product/techoverview.shtml). 
Results
Demographic data
Table 1 summarizes the patients’ demographic data and
neuropathological diagnoses. The mean age at death of the 38
men and 34 women was 78.7 ± 8.2 years. Before the first
consultation, the duration of symptoms varied between less
than six months to over 5 years, and did not appear to be related
to the diagnosis. The mean duration between the first MC
consultation and death was 3.2 ± 2.3 years. The AD group
survived the longest after the first MC consultation (4.1 years).
The AD group (and four patients with AgD) scored lowest on
the MMS, reflecting their primary neocortical impairments
and/or the more advanced stage of their disease. 
Relationship between clinical and pathological diagnoses 
The relationships between the clinical and neuropathological
diagnoses are shown in Table 2. 67.8 % (n = 42) of patients
received a neuropathological diagnosis of AD, VaD or mixed
dementia (AD and VaD) and AD + DLB. AD was the most
frequent diagnosis; 63 % of patients (n = 39) evidenced
neuropathological signs of AD, either in isolation (n = 29) or
with other histopathological hallmarks of dementia (e.g. VaD).
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Among the 29 AD cases, the Braak stage (42) and CERAD
plaque score (43) where as follows: Braak stage IV (n = 6), V
(n = 6) and VI (n = 17), CERAD plaque score C (n = 29). Thus,
according to the NIA-Reagan criteria [44] there was a high (n =
23) or  intermediate to high (n = 6) likelihood that dementia
was due to AD lesions in all our AD patients. Only 4.8 % of
patients (n = 3) were diagnosed with VaD. The prevalence of
DLB (8.1 %) and FTD (3.2 %) was lower than reported values
(10 - 25 % and 12 - 20 %, respectively) (14-17, 21).  This
difference may be attributable to geographical factors, as
epidemiological studies conducted in England or Scandinavia
report higher prevalence rates for DLB and FTD. 
Sensitivity and specificity of the clinical diagnosis of DAT
Despite the small cell sizes, the sensitivity and specificity of
the clinical diagnoses of DAT were estimated. Sensitivity refers
to the true positive rate, i.e. the number of patients having both
a clinical and neuropathological diagnosis of disease A divided
by the total number of patients having the neuropathological
diagnosis of disease A. Specificity refers to the true negative
rate, i.e. the number of patients having clinical and
neuropathological diagnosis other than diagnosis A divided by
the total number of patients with a neuropathological diagnosis
other than diagnosis A. The sensitivity and specificity of the
clinical diagnosis of DAT in the present sample were 75.9 %
and 60.6 %, respectively, and are similar to those reported in
previous studies (2-5). 
Age at death and polymorbidity
To evaluate the relationship between polymorbidity and age,
the sample of patients was split at the median age of 78 into
younger and older groups, and the corresponding numbers of
patients with no neuropathology, one neuropathological
diagnosis and more than one neuropathological diagnosis were
tabulated (see Table 3). Chi-squared analyses revealed that
while the frequencies of patients with single neuropathological
diagnoses were comparable in the younger and older groups 
(χ2 (df = 1) = .03; p = ns), significantly more older than
younger patients were diagnosed with multiple
neuropathological diagnoses (χ2 (df = 1) = 4.26; p < 0.05). 
Table 3
Comorbidities with advancing age.
Age at death
Number of neuropath- < 78 Jahre > 78 Jahre Total χ2
ological findings
0 1 3 4 
1 20 19 39 .03
> 1 5 14 19 4.26
Total 26 36 62
Discussion
The most common neuropathological diagnosis in the
present patient population was AD, either alone or associated
with other lesions, in 63 % of all patients. 34 % of patients
suffered from pure AD. The next most common cause of
dementia was the mixed etiology (AD and VaD) with 11.3 %,
followed by DLB (8%) and AgD in 6.5 %, and VaD in 4.8 % of
the patients. These results are consistent with previous
neuropathological studies (see Table 5). Moreover, the DLB
prevalence of 8 % is consistent with other reports from
hospital-based populations, which typically range from 10 to 
15 % (9,10,12). Other causes of dementia (CBD, FTD,
meningioma, hydrocephalus, PD and subdural hematoma) were
found in 11.2 % of the patients. Four patients (6.5 %) had no
pathological findings on autopsy. One of these patients (Braak
stage II) had been considered neurologically normal, one
patient had been clinically diagnosed with a subcortical
dementia syndrome with an ataxic gait, one patient (Braak
stage III) had been clinically diagnosed with AAMI, and one
patient had been clinically diagnosed with a depressive disorder
with frontal lobe dysfunction and showed status lacunaris on
MRI which was not confirmed in the neuropathological
examination. 
Table 4
Reported prevalence of the different forms of dementia.
AD mixed VaD DLB
Mölsä et al., 1985 [2] 48.3 % 10.3 % 19.0 % 0
Jellinger et al., 1990 [4]:
Psychiatric population 69.4 % 8.8% 9.5 % 0.7 %
Geriatric population 59.7 % 6.8 % 16.6 % 0
General population 56.5 % 8.7 % 18.3 % 1.3 %
Drach et al., 1997 [36] 35.6 % 15.3 % 5.1 % 13.6 %
Knopman et al., 2003 [8] 51.0 % 12.4 % 13.5 % 10.1 %
Gay et al., current study 46.7 % 11.3 % 4.8 % 8.0 %
In the present study, the sensitivity of the clinical diagnosis
of DAT was 75.9% and the specificity 60.6 %. In Table 5, we
compare the present results with those reported in other studies.
The relatively low specificity in the cited studies, i.e. the
discrepancy between the positive clinical findings and the
results of the neuropathological examination, indicates a
substantial symptomatological variation of associated brain
pathology. Lopez et al. (1) reported in a retrospective study an
increasing specificity (52 to 80 %) in the clinical diagnosis of
DAT over the last 20 years, while the sensitivity for the
diagnosis of DAT remained above 90%. This pattern was
attributed to the improvement in the diagnosis of non-DAT
dementias. 
Table 5
Comparison of sensitivities and specificities of the diagnosis of
Dementia of the Alzheimer Type (DAT) 
Sensitivity Specificity
Mölsä et al., 1985 [2] 0.71 0.73
Jellinger et al., 1990 [4]
Psychiatric population 0.92 0.60
Geriatric population 0.80 0.84
General population 0.82 0.78
Galasko et al., [5] 1994 0.78 0.48
Victoroff et al., [3] 1995 0.75 0.54
Lim et al., [37]1999 0.83 0.55
Gay et al., current study 0.76 0.61
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The diagnosis of DAT appears to be most accurate in
published studies: the diagnostic accuracy for of DLB has a low
sensitivity and a high specificity (14, 25, 26, 38), and the
specificity in diagnosing VaD ranges from 64 to 98 % while the
sensitivity remains low (i.e., 20 to 70 %) (5, 24, 27, 39). The
validity of the clinical diagnostic criteria for mixed dementia
remains controversial (14, 25, 26, 38). 
The present study found that polymorbidity increases with
increasing age at death. The diagnosis of patients suffering
from multiple dementia etiologies remains a challenging
endeavor (26, 39). While it seems logical to attribute the
dementia to the neuropathologic lesions found, it is worth
recalling that even considerable lesions may not cause a clinical
dementia syndrome (40). 
The patient group in the present study had several biases.
Firstly, not every patient had a follow-up examination.
Secondly, every patient who was seen in the MC was referred
by a physician (practitioner, hospital) for this specialist
examination; these patients most likely presented with a
complicated clinical picture that necessitated consultation with
a specialist center. Thirdly, nearly all patients who underwent
autopsy died in a hospital (92%). Thus, the autopsied subgroup
may have suffered from other systemic illnesses and may
therefore not be reflective of the memory clinic populations as
a whole. In Switzerland, patients who die at home or in an
institution are rarely autopsied. Finally, the present cohort
included polymorbid patients with acute illnesses or those that
suffered from a behavioral disorder, i.e. patients not suited for
nursing home placement and who instead required
gerontopsychiatric institutionalization. 
Conclusion
The present study investigated the validity of clinical
diagnoses of dementia in a group of consecutively autopsied
Memory Clinic patients. The sensitivity of the clinical
diagnosis for DAT was 75.9 % and the specificity 60.6 %.
Thus, the present results are similar to those reported in
previous studies (2-5). Older patients more commonly suffered
from multiple etiologies of dementia than younger patients.
This study reaffirms the need for internationally accepted
diagnostic criteria for dementia that are sensitive and specific.
The neuropathological investigation remains critical for the
determination of dementia etiology. 
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